Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant fimbrial adhesin dscCfaE is a donor strand-complemented form of the CfaE protein, which is the minor adhesive subunit located at the tip of CFA/I fimbriae from enterotoxigenic Escherichia coli (ETEC). This recombinant protein is engineered for increased stability and immunogenicity by fusing the C-terminal region of CfaB (the major pilin subunit) to the N-terminus of CfaE via a linker. The resulting molecule mimics the native conformation found on bacterial surfaces and serves as an antigen in vaccine formulations designed to prevent ETEC-induced diarrhea. The mechanism of action involves stimulating an immune response that generates neutralizing antibodies targeting ETEC adhesion to intestinal epithelial cells, thereby preventing colonization and subsequent diarrheal disease[2][3][5]. Clinical studies have shown that vaccines containing this antigen are safe and immunogenic in humans[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant fimbrial adhesin dscCfaE.